Pulmonary Fibrosis and Oxygen Therapy: Evidence, Benefits, and Daily Life

Pulmonary fibrosis progressively scars the lungs, making it harder to transfer oxygen into the bloodstream. As the disease advances, blood oxygen levels drop, first during exertion and eventually at rest. Supplemental oxygen therapy becomes one of the most important tools for managing symptoms and maintaining quality of life.

This article explains why pulmonary fibrosis causes low oxygen, when supplemental oxygen is prescribed, what the evidence says about its benefits, and what living with oxygen therapy looks like day to day.

Why Pulmonary Fibrosis Causes Low Oxygen

In healthy lungs, oxygen passes from the air sacs (alveoli) through a thin membrane into the surrounding capillaries. Carbon dioxide moves in the opposite direction. This gas exchange happens across a surface area roughly the size of a tennis court.

Pulmonary fibrosis replaces normal, flexible lung tissue with thick, stiff scar tissue. This scarring does two things that directly impair oxygenation:

1. Thickened gas exchange barrier. The membrane between the alveoli and capillaries becomes thicker, slowing the diffusion of oxygen into the blood. Carbon dioxide, which diffuses more easily, is less affected at first.
2. Reduced lung volume. Scarred lungs cannot expand fully. The total surface area available for gas exchange shrinks. Each breath moves less air, and less of that air reaches functioning alveoli.

The result is progressive hypoxemia: blood oxygen levels that decline over months and years. Initially, oxygen levels may be normal at rest but drop during physical activity (exertional desaturation). As fibrosis advances, resting oxygen levels fall too.

When Is Oxygen Therapy Prescribed?

The standard criteria for prescribing long-term oxygen therapy (LTOT) in pulmonary fibrosis follow established guidelines:

• Resting SpO2 below 88% or PaO2 at or below 55 mmHg
• SpO2 of 88 to 89% with evidence of cor pulmonale, right heart failure, or polycythemia (elevated red blood cell count)
• Exertional desaturation below 88% during a six-minute walk test, even if resting levels are normal

Your pulmonologist will typically determine oxygen needs through pulse oximetry at rest and during a walking test. Some patients need oxygen only during exercise or sleep. Others require it around the clock.

Types of Supplemental Oxygen Systems

System	How It Works	Best For
Stationary Concentrator	Pulls oxygen from room air, delivers via nasal cannula	Home use, continuous flow, nighttime
Portable Concentrator (POC)	Battery-powered, lightweight, pulse or continuous dose	Travel, errands, staying active
Compressed Gas Tanks	Pressurized oxygen in metal cylinders	Backup supply, short outings
Liquid Oxygen	Oxygen stored as liquid, converted to gas on delivery	High-flow needs, extended portability

Most pulmonary fibrosis patients start with a stationary concentrator at home and a portable unit for leaving the house. Your durable medical equipment (DME) provider will help set up the equipment and train you on its use.

Ambulatory Oxygen During Exertion

One of the most impactful uses of supplemental oxygen in pulmonary fibrosis is during physical activity. Even patients with acceptable resting oxygen levels often desaturate significantly during walking, climbing stairs, or any sustained effort.

Ambulatory oxygen during exertion can:

• Reduce breathlessness during activity
• Allow patients to walk farther and exercise longer
• Help maintain muscle strength and cardiovascular fitness
• Prevent the deconditioning cycle where breathlessness leads to inactivity, which leads to further deconditioning

A six-minute walk test with and without supplemental oxygen helps determine the right flow rate for activity. Many patients need a higher flow rate during exercise than at rest.

Evidence for Survival Benefit

The evidence for oxygen therapy extending life in pulmonary fibrosis is surprisingly thin. Unlike in COPD, where landmark trials (NOTT and MRC studies) demonstrated a clear survival benefit from long-term oxygen therapy, no equivalent large-scale trial has been completed for idiopathic pulmonary fibrosis (IPF).

“Studies reporting the use of long-term oxygen therapy in interstitial lung disease are at high risk of bias, and it was not possible to estimate its impact on survival.”
European Respiratory Review, 2017

Current guidelines recommend oxygen therapy for pulmonary fibrosis patients with significant hypoxemia, but this recommendation is based on physiological rationale and extrapolation from COPD data rather than robust IPF-specific evidence (Bell et al., 2017, doi:10.1183/16000617.0080-2016).

What the evidence does support:

• Improved exercise capacity in patients whose hypoxemia limits activity
• Reduced breathlessness during daily tasks
• Better quality of life for many patients, including improved mobility and ability to complete household tasks
• Maintained independence for longer as the disease progresses

A cohort study published in Scientific Reports (2023) evaluated prognostic factors in IPF patients introduced to oxygen therapy and found that the timing of oxygen initiation and baseline lung function at the time of prescription were important predictors of outcomes (Kato et al., 2023, doi:10.1038/s41598-023-40508-8).

Palliative Oxygen

In advanced pulmonary fibrosis, when curative options are limited or lung transplant is not feasible, oxygen therapy plays a palliative role. The goal shifts from extending life to maximizing comfort.

Palliative oxygen can:

• Ease the sensation of air hunger, which is one of the most distressing symptoms in end-stage fibrosis
• Allow patients to remain at home rather than in a hospital setting
• Support meaningful activities and time with family
• Reduce anxiety associated with severe breathlessness

High-flow nasal cannula (HFNC) therapy has emerged as an option for IPF patients with respiratory failure. A study published in Internal Medicine (2020) found that HFNC improved oxygenation and reduced respiratory rate in IPF patients experiencing acute exacerbations (Koyauchi et al., 2020, doi:10.2169/internalmedicine.3737-19).

Living With Oxygen and Pulmonary Fibrosis

Adjusting to supplemental oxygen is a process. Most patients report an initial period of resistance or frustration followed by recognition that the benefits outweigh the inconveniences.

Practical Tips

• Monitor with a pulse oximeter. Keep a handheld pulse oximeter at home. Aim to maintain SpO2 above 90% throughout the day and night
• Use oxygen during pulmonary rehabilitation. Exercise programs designed for lung disease patients are more effective when oxygen needs are properly managed
• Plan for outings. Check battery life on portable units before leaving. Carry extra batteries or a car charger
• Manage nasal dryness. Long-term nasal cannula use can dry out nasal passages. A humidifier bottle on your concentrator or saline nasal spray can help
• Keep equipment maintained. Replace filters, tubing, and cannulas on the schedule your DME provider recommends

Emotional Impact

Starting oxygen therapy can feel like a visible marker of disease progression. Many patients describe feelings of self-consciousness, loss of independence, or grief. These responses are normal and worth discussing with your care team, a counselor, or a pulmonary fibrosis support group.

The Pulmonary Fibrosis Foundation and American Lung Association both offer patient support resources, including peer mentoring programs that connect newly diagnosed patients with others who have navigated similar challenges.

Lung Transplant Considerations

For eligible patients, lung transplantation remains the only treatment that can halt the progression of pulmonary fibrosis. The need for supplemental oxygen, particularly escalating requirements, is one factor that transplant centers evaluate when assessing candidacy and timing.

Patients on oxygen therapy should discuss transplant evaluation with their pulmonologist, especially if:

• Oxygen requirements are increasing over time
• Exercise capacity is declining despite optimal medical management
• Quality of life is significantly impaired
• They are under age 65 (though age cutoffs vary by center)

Being on oxygen does not disqualify a patient from transplant. In fact, increasing oxygen needs can be an important signal to accelerate the evaluation process.

The Bottom Line

Supplemental oxygen is a cornerstone of symptom management in pulmonary fibrosis. While the evidence for a direct survival benefit is weaker than many patients expect, the improvements in breathlessness, exercise capacity, and daily functioning are well-documented and clinically meaningful.

The most important step is getting properly assessed. A six-minute walk test and resting oximetry can determine whether oxygen will help, and at what flow rate. From there, working with a good DME provider and pulmonary rehabilitation team can make the transition smoother and more effective.

References

• Bell, E.C., et al. (2017). Oxygen therapy for interstitial lung disease: a systematic review. European Respiratory Review, 26(143), 160080. doi:10.1183/16000617.0080-2016
• Kato, E., et al. (2023). Cohort study to evaluate prognostic factors in idiopathic pulmonary fibrosis patients introduced to oxygen therapy. Scientific Reports, 13, 13424. doi:10.1038/s41598-023-40508-8
• Koyauchi, T., et al. (2020). High-flow nasal cannula oxygen therapy in idiopathic pulmonary fibrosis patients with respiratory failure. Internal Medicine, 59(7), 901-907. doi:10.2169/internalmedicine.3737-19
• Visca, D., et al. (2018). Ambulatory oxygen in interstitial lung disease. European Respiratory Review, 27(148), 170089.
• Pulmonary Fibrosis Foundation. Supplemental Oxygen. pulmonaryfibrosis.org